Creative Planning
PTCT icon

Creative Planning’s PTC Therapeutics PTCT Stock Holding History

Creative Planning’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-500
Closed -$2K – 4858
2016
Q4 		$2K Buy
+500
New +$5.25K ﹤0.01% 4293

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Creative Planning's PTCT Position: Q1 2026 in Review

Creative Planning increased its PTC Therapeutics (PTCT) stake by 12% in Q1 2026, buying an estimated $314K and bringing the position to 42,196 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

Creative Planning first reported a position in PTCT in Q1 2015 and has held it in 28 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Creative Planning held 42,196 shares of PTC Therapeutics worth $2.87M as of Q1 2026.
  • Creative Planning bought 4,430 PTC Therapeutics shares in Q1 2026, an estimated $314K.
  • PTC Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1606 holding.
  • Creative Planning first reported a position in PTC Therapeutics in Q1 2015 and has held it in 28 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.